IL2 and systemic lupus erythematosus: An initial study in which patients with SLE were given low-dose IL-2 reported an increase in the number of Treg cells, which was associated with an apparent decrease in a clinical SLE disease index71, suggesting that such an approach may warrant evaluation in future clinical trials.